Table 1.
Demographic and clinical characteristics of patients with systemic rheumatic disease at the time of SARS-CoV-2 vaccination.
| Characteristic | All Rheumatic Disease Patients (N = 11,468) |
|---|---|
| Age (mean, SD, years) | 60.17 (15.3) |
| Female | 8620 (75.2) |
| Race | |
| White | 9490 (82.8) |
| Black or African American | 628 (5.5) |
| Asian | 417 (3.6) |
| Other | 620 (5.4) |
| Unknown | 313 (2.7) |
| Hispanic or Latinx ethnicity | 787 (6.9) |
| Body mass index (mean, SD, kg/m2) | 28.59 (6.7) |
| Smoking status | |
| Never | 6572 (57.3) |
| Former | 4232 (36.9) |
| Current | 664 (5.8) |
| Charlson Comorbidity Index (median [IQR]) | 1 (1,3) |
| Comorbidities | |
| Hypertension | 4565 (39.8) |
| Diabetes | 1541 (13.4) |
| Asthma | 1438 (12.5) |
| Malignancy excluding non-melanoma skin cancer | 1236 (10.8) |
| Chronic kidney disease | 1127 (9.8) |
| Coronary artery disease | 1100 (9.6) |
| Obstructive sleep apnea | 1089 (9.5) |
| Heart failure | 607 (5.3) |
| Interstitial lung disease | 574 (5.0) |
| Chronic obstructive pulmonary disease | 558 (4.9) |
| Non-melanoma skin cancer | 408 (3.6) |
| COVID-19 infection prior to index date | 560 (4.9) |
| SARS-CoV-2 Vaccine | |
| BNT162b2 (Pfizer-BioNTech) | 6080 (53.0) |
| mRNA-1273 (Moderna) | 4588 (40.0) |
| Johnson & Johnson-Janssen | 800 (7.0) |
| Calendar time of index date | |
| Before March 31, 2021 | 6195 (54.0) |
| April 1 to June 30, 2021 | 4801 (41.9) |
| July 1 to September 30, 2021 | 356 (3.1) |
| October 1 to November 15, 2021 | 116 (1.0) |